SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis
SynAct Pharma AB (“SynAct”) today announced that recruitment in the BEGIN study in Rheumatoid Arthritis (RA) has been extended into the first half of September in order to reach the goal of 105 randomized patients, of which 98 have been recruited to date. As a result of the continued recruitment, reporting of key results previously expected to take place by the end of Q3 will be postponed to early Q4 after which a press release with top-line results will be released immediately. SynAct applauds the efforts of its clinical sites and their patients to keep this important evaluation of AP1189